Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| West Nile Virus Infections Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for West Nile Virus Infections Overview | 8 | 1 |
| Pipeline Products for West Nile Virus Infections Comparative Analysis | 9 | 1 |
| West Nile Virus Infections Therapeutics under Development by Companies | 10 | 1 |
| West Nile Virus Infections Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| West Nile Virus Infections Pipeline Products Glance | 12 | 2 |
| Clinical Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| West Nile Virus Infections Products under Development by Companies | 14 | 1 |
| West Nile Virus Infections Products under Investigation by Universities/Institutes | 15 | 1 |
| West Nile Virus Infections Companies Involved in Therapeutics Development | 16 | 5 |
| CEL-SCI Corporation | 16 | 1 |
| Hemispherx Biopharma, Inc. | 17 | 1 |
| Kineta, Inc. | 18 | 1 |
| Nanotherapeutics, Inc. | 19 | 1 |
| Plex Pharmaceuticals, Inc. | 20 | 1 |
| West Nile Virus Infections Therapeutics Assessment | 21 | 9 |
| Assessment by Monotherapy Products | 21 | 1 |
| Assessment by Target | 22 | 2 |
| Assessment by Mechanism of Action | 24 | 2 |
| Assessment by Route of Administration | 26 | 2 |
| Assessment by Molecule Type | 28 | 2 |
| Drug Profiles | 30 | 33 |
| Alferon LDO Drug Profile | 30 | 2 |
| BG-323 Drug Profile | 32 | 1 |
| CEL-1000 Drug Profile | 33 | 2 |
| FDX-000 Drug Profile | 35 | 1 |
| HydroVax-001 Drug Profile | 36 | 1 |
| interferon alfa-n3 Drug Profile | 37 | 4 |
| KIN-1148 Drug Profile | 41 | 1 |
| KIN-1400 Drug Profile | 42 | 2 |
| Monoclonal Antibody for West Nile Virus Infections Drug Profile | 44 | 1 |
| rintatolimod Drug Profile | 45 | 9 |
| RL-15A Drug Profile | 54 | 1 |
| Small Molecule to Inhibit NS2B-NS3 Protease for Dengue, Zika and West Nile Virus Infection Drug Profile | 55 | 1 |
| Small Molecules for Viral Infections Drug Profile | 56 | 1 |
| Small Molecules to Inhibit NS3 Protease for Dengue and West Nile Virus Infections Drug Profile | 57 | 1 |
| Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections Drug Profile | 58 | 1 |
| Synthetic Peptide for Dengue Virus and West Nile Virus Infections Drug Profile | 59 | 1 |
| Tatbeclin-1 Drug Profile | 60 | 1 |
| West Nile virus vaccine Drug Profile | 61 | 1 |
| West Nile virus vaccine Drug Profile | 62 | 1 |
| West Nile Virus Infections Dormant Projects | 63 | 3 |
| West Nile Virus Infections Product Development Milestones | 66 | 4 |
| Featured News &Press Releases | 66 | 1 |
| Jul 06, 2015: NIH-funded vaccine for West Nile Virus enters human clinical trials | 66 | 1 |
| May 05, 2014: Alferon N Effective Against MERS Virus In-Vitro | 67 | 1 |
| Sep 12, 2013: Hemispherx Announces Initial Test Results in Biosecurity/Biodefense Arena | 67 | 1 |
| Sep 06, 2011: Hemispherx Enters Into Strategic Alliance With Armada Health Care For Alferon N Injection | 68 | 1 |
| Apr 20, 2010: Kineta Scientist to Present Novel Antiviral Research Findings at International Conference | 69 | 1 |
| Appendix | 70 | 2 |
| Methodology | 70 | 1 |
| Coverage | 70 | 1 |
| Secondary Research | 70 | 1 |
| Primary Research | 70 | 1 |
| Expert Panel Validation | 70 | 1 |
| Contact Us | 70 | 1 |
| Disclaimer | 71 | 1 |